Increased serum levels of serine enantiomers in patients with depression

Acta Neuropsychiatrica

Volumn 28, Issue 3, 2016, Pages 173-178

  Hashimoto, Kenji ^a   Yoshida, Taisuke ^b   Ishikawa, Masatomo ^b   Fujita, Yuko ^a   Niitsu, Tomihisa ^b   Nakazato, Michiko ^a,b,c   Watanabe, Hiroyuki ^a,b   Sasaki, Tsuyoshi ^b,c   Shiina, Akihiro ^b,c   Hashimoto, Tasuku ^b   Kanahara, Nobuhisa ^a,b   Hasegawa, Tadashi ^b   Enohara, Masayo ^b   Kimura, Atsushi ^b   Iyo, Masaomi ^a,b,c  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

biomarker; d serine; depression; l serine; NMDA receptor

Indexed keywords

ADULT; ANALYTIC METHOD; ARTICLE; BRAIN REGION; BRAIN SIZE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FORCEPS MINOR; FRACTIONAL ANISOTROPY; HUMAN; IMAGING; MALE; OBSESSIVE COMPULSIVE DISORDER; T2 FLUID ATTENUATED INVERSION RECOVERY; TRACT BASED SPATIAL STATISTICS; VOXEL BASED MORPHOMETRY; WHITE MATTER; BLOOD; CASE CONTROL STUDY; DEPRESSION; MIDDLE AGED; STEREOISOMERISM; YOUNG ADULT;

BIOLOGICAL MARKER; GLUTAMIC ACID; GLUTAMINE; GLYCINE; SERINE;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; DEPRESSION; FEMALE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HUMANS; MALE; MIDDLE AGED; SERINE; STEREOISOMERISM; YOUNG ADULT;

EID: 84945541070     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2015.59     Document Type: Article

References (26)

1. SANACORA G, ZARATE CA, KRYSTAL JH, MANJI HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-437.
2. HASHIMOTO K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105-123.
3. HASHIMOTO K, MALCHOW B, FALJAI P et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263:367-377.
4. KRYSTAL JH, SANACORA G, DUMAN RS. Rapid-acting antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
5. HASHIMOTO K. The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 2014;12:72-73.
6. YANG C, HASHIMOTO K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl) 2014;231:2041-2042.
7. YANG C, SHIRAYAMA Y, ZHANG JC et al. R-ketamine: a rapidonset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 2015;5:e632.
8. HERESCO-LEVY U, GELFIN G, BLOCH B et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013;16:501-506.
9. HASHIMOTO K, SAWA A, IYO M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-1316.
10. PÅLSSON E, JAKOBSSON J, SÖDERSTEN K et al. Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur Neuropsychopharmacol 2015;25:133-140.
11. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
12. UEDA N, SUDA A, NAKAGAWA M et al. Reliability, validity and clinical utility of a Japanese version of the Social Adaptation Self-evaluation Scale as calibrated using the Beck Depression Inventory. Psychiatry Clin Neurosci 2011;65:624-629.
13. BOSC M. Assessment of social functioning in depression. Compr Psychiatry 2000;41:63-69.
14. YOSHIDA T, SUGA M, ARIMA K et al. Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. PLoS One 2011;6:e20469.
15. YOSHIDA T, ISHIKAWA M, NIITSU T et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012;7:e42676.
16. FUKUSHIMA T, KAWAI J, IMAI K, TOYO'OKA T. Simultaneous determination of D- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed Chromatogr 2004;18:813-819.
17. MAES M, DE BACKER G, SUY E, MINNER B. Increased plasma serine concentration in depression. Neuropsychobiology 1995;31:10-15.
18. SUMIYOSHI T, ANIL AE, JIN D et al. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 2004;7:1-8.
19. MITANI H, SHIRAYAMA Y, YAMADA T et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1155-1158.
20. ALTAMURA C, MAES M, DAI J, MELTZER HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995;5(Suppl.):71-75.
21. HASHIMOTO K. Targeting of NMDA receptors in new treatments of schizophrenia. Expert Opin Ther Targets 2014;18:1049-1063.
22. WAZIRI R, MOTT J, WILCOX J. Differentiation of psychotic from nonpsychotic depression by a biological marker. J Affect Disord 1985;9:175-180.
23. HASHIMOTO K, FUKUSHIMA T, SHIMIZU E et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-576.
24. MOADDEL R, LUCKENBAUGH DA, XIE Y et al. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) 2015;232:399-409.
25. HASHIMOTO K. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology (Berl) 2014;231:4081-4082.
26. HASHIMOTO K. Serine enantiomers as diagnostic biomarkers for schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2015; doi: 10.1007/s00406-015-0602-4.